Cll In Memoriam: Remembering Hematologist Steve E Coutre, Md

Shanafelt and Liedtke, kindly attended to answer all questions and hear their tributes. Here is the obituary from Stanford Medicine that provides some highlights of his life and skilled career. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older sufferers with untreated CLL.

Steve Coutre, MD. handed away on November ninth in Palo Alto, California surrounded by family at age 62 from complications of leukemia and COVID-19. Steven Coutre, MD, a professor of hematology on the Stanford School of Medicine, died Nov. 9 in Palo Alto, California, from issues of leukemia and COVID-19. It is with a heavy heart that I share the information of the premature demise of Dr. Steven Coutre on November 9th, 2021 after a prolonged sickness and hospitalization. It is with nice sadness and respect that I write to tell you that our beloved Dr. Steven Coutre has passed away.

Our cancer middle leadership may even be rounding regularly to see if we will give you some other assist during this troublesome time. Below we additionally share an message despatched by Dr. Ravi Majeti, chief of hematology which incorporates extra help providers for college workers and trainees. Our hearts are with Steve‚Äôs household and all of us who’re deeply saddened by his loss. I was concerned in all of the early trials with idelalisib.

Ibrutinib is a first-in-class, once-daily inhibitor of BTK accredited in the United States for remedy of CLL/SLL. RESONATE-2 is a phase 3 research evaluating first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary outcomes (median follow-up, 18.four months) demonstrated ibrutinib decreased danger of progressive illness or dying by 84% . Events of scientific interest , together with cardiovascular occasions, had been similar in each acalabrutinib arms . In addition, the cumulative incidences of atrial fibrillation and hypertension over time were low and similar across therapy teams (Supplementary Fig.4). Ibrutinib, a B-cell receptor pathway inhibitor, is accredited within the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and permits for therapy with out chemotherapy.

Coutre says a remarkable accomplishment can be for the average patient, who’s no less than 70 years of age and in want of initial remedy, to find a way to obtain an oral, well-tolerated agent similar to ibrutinib or idelalisib. Though this agent might not get rid of their disease best burger in plano, it might have the potential to handle it for the rest of their life. With brokers ibrutinib and idelalisib proving to be efficacious in remedy of CLL, Coutre explains extra sufferers are steering away from chemotherapy as a remedy possibility. There can additionally be more tolerability with these brokers, he says.

Comments are closed.